Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.62 USD
Change Today +0.05 / 1.09%
Volume 6.6K
WGBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

wafergen bio-systems inc (WGBS) Key Developments

WaferGen Bio-Systems, Inc. Announces an Industrial Partnership with Procter & Gamble

WaferGen Bio-systems, Inc. announced an industrial partnership with Procter & Gamble whereby Procter & Gamble will utilize WaferGen's SmartChip MyDesign quantitative PCR System to conduct various gene expression and other studies. As the amount of genomics data increases with the use of Next Generation Sequencing and microarrays, the need for high-throughput target validation becomes more acute. WaferGen's SmartChip platform offers two products that enhance these efforts, SmartChip MyDesign for qPCR and SmartChip TE for NGS sample preparation.

WaferGen Bio-systems, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015

WaferGen Bio-systems, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $1,611,720 against $490,465 a year ago. The increase is primarily due to an increase in SmartChip revenue of $0.6 million, plus Apollo revenue of $0.5 million compared to none in 2013. Operating loss was $3,518,046 against $2,134,113 a year ago. Net loss before provision for income taxes was $3,263,301 against income of $1,489,875 a year ago. Net loss attributable to common stockholders was $3,263,301 against income of $4,385,275 a year ago. Net loss per share basic and diluted was $0.58 against diluted earnings per share of $2.46 a year ago. For the year, the company reported total revenues of $6,001,342 against $1,304,747 a year ago. This growth was primarily driven by an increase in product revenue of $4.7 million, or 550%, to $5.5 million. Operating loss was $12,449,715 against $9,922,443 a year ago. Net loss before provision for income taxes was $10,689,763 against $16,259,931 a year ago. Net loss attributable to common stockholders was $10,692,863 against $17,712,066 a year ago. Net loss per share basic and diluted was $4.17 against $58.16 a year ago. The decrease in net loss was primarily due to the increase in revenue and the absence of one-time charges related to corporate restructuring incurred in the third quarter of 2013. The company currently expects full year 2015 revenue of $8.0 million to $8.5 million, which excludes revenue from single cell products, presently being developed.

WaferGen Bio-systems, Inc. to Report Q4, 2014 Results on Mar 16, 2015

WaferGen Bio-systems, Inc. announced that they will report Q4, 2014 results After-Market on Mar 16, 2015

WaferGen Bio-systems, Inc., Q4 2014 Earnings Call, Mar 16, 2015

WaferGen Bio-systems, Inc., Q4 2014 Earnings Call, Mar 16, 2015

WaferGen Bio-Systems Announces Positive Results of a Single Cell Study Utilizing its SmartChip(TM) Technology

WaferGen Bio-systems announced that it has produced positive results in a study aimed at validating the utility of its SmartChipTM technology for isolating and studying single cells via Next-Generation Sequencing (NGS). The study was conducted in collaboration with the Broad Institute, and the findings will be presented at the 2015 Advances in Genome Biology & Technology (AGBT) meeting to be held February 25-28 in Marco Island, Florida. In a proof of concept study, WaferGen has engineered a solution for depositing single cells into the individual SmartChipTM wells in a directed fashion, to achieve far greater chip utilization. At this level of efficiency, each chip could produce more than 4,000 single cells for analysis. The cell's genetic composition was then successfully analyzed with the NGS method by adapting the Single Cell RNA Barcoding and Sequencing (SCRB-Seq) technology pioneered by the Broad Institute. SCRB-Seq measurements have already resulted in critical discoveries of novel cell types that play an important role in disease mechanisms.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WGBS:US $4.62 USD +0.05

WGBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $3.01 USD -0.02
Exiqon A/S kr10.60 DKK +0.50
NanoString Technologies Inc $12.11 USD -0.09
Pacific Biosciences of California Inc $5.76 USD -0.14
Sequenom Inc $4.52 USD -0.10
View Industry Companies
 

Industry Analysis

WGBS

Industry Average

Valuation WGBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WAFERGEN BIO-SYSTEMS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.